(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 December 2012 (20.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/174001 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2012/042068

(22) International Filing Date:
12 June 2012 (12.06.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/496,249 13 June 2011 (13.06.2011) US

(71) Applicant *(for all designated States except US)*: **ABGENOMICS COOPERATIEF U.A.** [NL/NL]; Strawinskylaan 3111, NL-1077 ZX Amsterdam (NL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BASSARAB, Stefan** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **ENENKEL, Barbara** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **GARIDEL, Patrick** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **SCHOTT, Heidrun** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **SINGH, Sanjaya** [US/US]; c/o VP, IP, Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **LITZENBURGER, Tobias** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(74) Agent: **EL-HAYEK, Roque**; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

(57) **Abstract**: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL- 1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL- 1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.

WO 2012/174001 A1